The 2b/3 trial was initiated in Australia because the Australian government provided a significant subsidy to trial costs; Missling was husbanding his limited resources. I believe he expanded it to the other foreign sites after that since it remained less expensive to choose the trial sites abroad than in the U.S., and given the fact that the FDA commonly recognizes such trials so long as our domestic protocols, etc., are followed.
At one point some years ago, Missling explained the slow pace of the 2b/3 rollout as being dictated by his then-limited funds. Missling historically has put a high value on Anavex's financial independence and has avoided dilution to the extent possible -- no matter whether this causes stockholders' short term frustration or not.
Market Data 
Markets 
AI
